Baseline patient characteristics
| Characteristic . | No.* . | % . |
|---|---|---|
| Total patients | 45 | |
| Median age, y (range) | 50 (20-69) | |
| Male/female | 30/15 | |
| Median weight, kg (range) | 80 (41-125) | |
| Race | ||
| White | 32 | 71 |
| Black | 9 | 20 |
| Other | 4 | 9 |
| Performance status | ||
| 0 | 30 | 67 |
| 1 | 15 | 33 |
| HCT-CI score | ||
| 0-2 | 34 | 75 |
| 3 or more | 11 | 25 |
| Diagnosis | ||
| AML/MDS | 29 | 64 |
| ALL | 7 | 16 |
| CLL | 2 | 4 |
| Lymphoma | 5 | 11 |
| CML myeloid crisis | 1 | 2 |
| CIMF | 1 | 2 |
| Stage of disease | ||
| CR1 | 14 | 31 |
| CR2 or CR3 | 5 | 11 |
| PR | 5 | 11 |
| Refractory/untreated relapse | 21 | 47 |
| Active disease | 26 | 58 |
| Prior transplantation | 7 | 16 |
| Prior intensive chemotherapy | 40 | 88 |
| Characteristic . | No.* . | % . |
|---|---|---|
| Total patients | 45 | |
| Median age, y (range) | 50 (20-69) | |
| Male/female | 30/15 | |
| Median weight, kg (range) | 80 (41-125) | |
| Race | ||
| White | 32 | 71 |
| Black | 9 | 20 |
| Other | 4 | 9 |
| Performance status | ||
| 0 | 30 | 67 |
| 1 | 15 | 33 |
| HCT-CI score | ||
| 0-2 | 34 | 75 |
| 3 or more | 11 | 25 |
| Diagnosis | ||
| AML/MDS | 29 | 64 |
| ALL | 7 | 16 |
| CLL | 2 | 4 |
| Lymphoma | 5 | 11 |
| CML myeloid crisis | 1 | 2 |
| CIMF | 1 | 2 |
| Stage of disease | ||
| CR1 | 14 | 31 |
| CR2 or CR3 | 5 | 11 |
| PR | 5 | 11 |
| Refractory/untreated relapse | 21 | 47 |
| Active disease | 26 | 58 |
| Prior transplantation | 7 | 16 |
| Prior intensive chemotherapy | 40 | 88 |
HCT-CI indicates hematopoietic cell transplantation–specific comorbidity index; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CIMF, chronic idiopathic myelofibrosis; CR, complete response; and PR, partial response.
No. represents number of patients unless otherwise specified.